Cancer News and Research

Latest Cancer News and Research

BioAlliance Pharma SA signs partnership agreement with Therabel Group

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today an exclusive partnership agreement with Therabel Group for the European commercialization rights of Loramyc® and Setofilm® including France and the associated French commercial structure to a newly established entity, Therabel Hôpital Pharma.

6 Apr 2010

Study: Carbon nanotubes degraded by MPO enzyme induce less inflammation

A team of Swedish and American scientists has shown for the first time that carbon nanotubes can be broken down by an enzyme - myeloperoxidase (MPO) - found in white blood cells.

6 Apr 2010

Emory University researchers develop experimental clinical test for XMRV

The recently discovered retrovirus, xenotropic murine leukemia virus-related virus (XMRV), has been identified in some prostate cancer patients. In light of conflicting data concerning XMRV, standardized diagnostic testing is important to identify patients in which XMRV is present and to determine whether it plays a role in the incidence of prostate cancer.

6 Apr 2010

U.S. Marshals seizes unapproved drug products

At the request of the U.S. Food and Drug Administration, U.S. Marshals on March 31 seized a range of consumer products, including creams, capsules, tablets, gum, throat spray, and shampoos from a Haywood, Wis., manufacturer.

6 Apr 2010

Humana adopts radiology benefit management programs to reduce unnecessary radiation exposure

Humana Inc. has reduced unnecessary radiation exposure for its members by the equivalent of more than five million chest x-rays since 2004, demonstrating how health benefits companies can lead the way in improving the quality and safety of health.

6 Apr 2010

Research may help scientists understand the mechanism behind cellular differentiation

Multipotent stem cells have the capacity to develop into different types of cells by reprogramming their DNA to turn on different combinations of genes, a process called "differentiation."

6 Apr 2010

Officials focus on inequalities in medical research

"After years of individual cancer centers exploring ways to recruit more people from minority populations for cancer studies, $3.8 million in federal stimulus money has been awarded to five institutions — including M.D. Anderson (Cancer Center at the University of Texas) — to work on the issue together for the next two years. The National Center on Minority Health and Health Disparities, part of the National Institutes of Health, funded the project."

6 Apr 2010

Exposure to certain chemicals may lead to early pubertal development

Researchers at Mount Sinai School of Medicine have found that exposure to three common chemical classes-phenols, phthalates and phytoestrogens-in young girls may disrupt the timing of pubertal development, and put girls at risk for health complications later in life.

6 Apr 2010

Unilife's Unitract 1mL Insulin Syringes receive 510(k) market clearance

Unilife Corporation today announced it has received from the U.S. Food and Drug Administration 510(k) market clearance for the Unitract™ 1mL Insulin Syringes assembled at its Lewisberry, PA manufacturing facility.

6 Apr 2010

Rice University's nano-bio-chip 93% specific in detecting patients with premalignant lesions

The gentle touch of a lesion on the tongue or cheek with a brush can help detect oral cancer with success rates comparable to more invasive techniques, according to preliminary studies by researchers at Rice University, the University of Texas Health Science Centers at Houston and San Antonio and the University of Texas M.D. Anderson Cancer Center.

6 Apr 2010

Cephalon acquires biotechnology company, Ception Therapeutics

Cephalon, Inc. announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc. and that Ception is now a wholly-owned subsidiary of Cephalon.

6 Apr 2010

Chinese SFDA approves Erye Pharmaceutical to manufacture generic Cloxapen

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced that its Suzhou Erye Pharmaceutical subsidiary ("Erye") recently received approval from the State Food and Drug Administration (SFDA) in China to manufacture the sterile active pharmaceutical ingredient (API) of the anti-infective cloxacillin sodium.

5 Apr 2010

Washington, D.C, hosts 7th Annual World Health Care Congress

With the most sweeping changes to national health care policy now law, the 7th World Health Care Congress will feature the first post-reform gathering of the nation's top health care executives from all industry sectors.

5 Apr 2010

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine.

5 Apr 2010

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

5 Apr 2010

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital. New investors Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital also joined the round. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma.

5 Apr 2010

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.

5 Apr 2010

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Halozyme Therapeutics secures multiple commercial supply agreements for rHuPH20

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the execution of multiple commercial supply agreements with its existing manufacturing partners. Halozyme amended an existing commercial supply agreement with Avid Bioservices, Inc., entered into a new commercial supply agreement with Avid and entered into a new commercial supply agreement with Cook Pharmica LLC.

5 Apr 2010